Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2020

01-03-2020 | Thyroidectomy | Original Article

Variations in radioiodine ablation: decision-making after total thyroidectomy

Authors: O. Maas, F. Forrer, M. Maas, C. M. Panje, J. Blautzik, M. Brühlmeier, I. Engel-Bicik, L. Giovanella, A. Haldemann, M. E. Kamel, S. Kneifel, C. Rottenburger, N. Schaefer, M. A. Walter, S. Weidner, P. M. Putora

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2020

Login to get access

Abstract

Background

The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.

Methods

We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies.

Results and Conclusion

We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
Literature
1.
Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRef
2.
Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94(8):692–700.CrossRef
3.
Hay ID, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–8.CrossRef
4.
Gerstein HC, et al. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–76.CrossRef
5.
Sacks W, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20(11):1235–45.CrossRef
6.
Dalac A, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97(5):1526–35.CrossRef
7.
Schmidt M, et al. A matter of controversy: is radioiodine therapy favorable in differentiated thyroid carcinoma? J Nucl Med. 2018;59(8):1195–201.CrossRef
8.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.CrossRef
9.
Hundsberger T, et al. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale. J Neurol. 2019.
10.
Zumstein V, et al. Surgical management of urolithiasis - a systematic analysis of available guidelines. BMC Urol. 2018;18(1):25.CrossRef
11.
Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017;123(3):372–81.CrossRef
12.
Luster M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941.CrossRef
13.
Verburg FA, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43(6):1001–5.CrossRef
14.
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993. 114;(6):1050–7.
15.
Hay ID, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088–95.PubMed
16.
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.CrossRef
17.
D’Avanzo A, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14(6):453–8.CrossRef
18.
Putora PM, Oldenburg J. Swarm-based medicine. J Med Internet Res. 2013;15(9):e207.CrossRef
19.
Glatzer M, et al. Decision-making criteria in oncology. Oncology. 2018;1–9.
20.
Panje CM, et al. Applied swarm-based medicine: collecting decision trees for patterns of algorithms analysis. BMC Med Res Methodol. 2017;17(1):123.CrossRef
21.
Steffen T, et al. Diagnostic nodes of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among colorectal cancer patients: a Swiss National Multicenter Survey. Clin Colorectal Cancer. 2019.
22.
Rothermundt C, et al. Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes. Oncologist. 2015;20(9):1028–35.CrossRef
23.
Hundsberger T, et al. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neuro-Oncol. 2016;126(1):175–83.CrossRef
24.
Panje CM, et al. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. 2015;191(10):778–86.CrossRef
25.
Putora PM, et al. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019;135:74–7.CrossRef
26.
Putora PM, et al. Objective consensus from decision trees. Radiat Oncol. 2014;9:270.CrossRef
27.
Nikiforov YE, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.CrossRef
28.
Tuttle RM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461–70.CrossRef
29.
Dietlein M, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4. Nuklearmedizin. 2016;55(3):77–89.CrossRef
30.
Tuttle RM. Controversial issues in thyroid cancer management. J Nucl Med. 2018;59(8):1187–94.CrossRef
31.
(NCCN), N.C.C.N., Thyroid carcinoma, in Thyroid Carcinoma (Version 2.2018). 2018.
32.
Vuong HG, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-a meta-analysis. Clin Endocrinol. 2017;87(5):411–7.CrossRef
33.
Zulewski H, et al. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. Swiss Med Wkly. 2019;149:w14700.PubMed
Metadata
Title
Variations in radioiodine ablation: decision-making after total thyroidectomy
Authors
O. Maas
F. Forrer
M. Maas
C. M. Panje
J. Blautzik
M. Brühlmeier
I. Engel-Bicik
L. Giovanella
A. Haldemann
M. E. Kamel
S. Kneifel
C. Rottenburger
N. Schaefer
M. A. Walter
S. Weidner
P. M. Putora
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04557-4

Other articles of this Issue 3/2020

European Journal of Nuclear Medicine and Molecular Imaging 3/2020 Go to the issue

Short Communication

New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide

Book Review

ATLAS OF PET-CT, A Quick Guide to Image Interpretation

Original Article

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

Original Article

The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients

Guidelines

[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0

Original Article

Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas